LXRX Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. (LXRX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
Where they traded
Last open-market purchase: February 25, 2026 , by DEBBANE RAYMOND .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| DEBBANE RAYMOND | Director | Buy | 2,000 | $1.49 | $3.0K | 1,906,186 | |
| DEBBANE RAYMOND | Director | Buy | 100,000 | $1.47 | $147.0K | 1,904,186 | |
| DEBBANE RAYMOND | Director | Buy | 100,000 | $1.48 | $147.8K | 1,804,186 | |
| DEBBANE RAYMOND | Director | Buy | 50,000 | $1.44 | $72.0K | 1,704,186 | |
| DEBBANE RAYMOND | Director | Buy | 133,688 | $1.32 | $176.5K | 1,654,186 | |
| DEBBANE RAYMOND | Director | Buy | 76,857 | $1.31 | $100.5K | 1,520,498 | |
| DEBBANE RAYMOND | Director | Buy | 57,952 | $1.31 | $75.9K | 1,443,641 | |
| Buy | 1,538,462 | $1.30 | $2.0M | 1,538,462 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.